Publications

• MarketCheck – Summer 2024
  August 2024
  Andrew L. Bab
  ,
  Gregory V. Gooding
  ,
  Jyotin Hamid
  ,
  Emily F. Huang
  ,
  Stephen M. Jordan
  ,
  Maurizio Levi-Minzi
  ,
  Timothy McIver
  ,
  Frank Mitchell
  ,
  Maura Kathleen Monaghan
  ,
  Jeffrey J. Rosen
  ,
  Zachary H. Saltzman
  ,
  Shannon Rose Selden
  ,
  Matthew J. Sorensen
  ,
  Katherine Durnan Taylor
  ,
  Alison E. Buckley-Serfass
  ,
  Caroline P. Geiger
  ,
  Caitlin Gibson
  ,
  Anne-Mette Heemsoth
  ,
  Tricia Bozyk Sherno
  ,
  Jacob W. Stahl
  ,
  Jillian Mulroy Wright
  ,
  Ilya Balabanovsky
  ,
  Marisa Demko
  ,
  Katrina Mari Kaczynski
  ,
  Rekha Korlipara
• Debevoise & Plimpton Special Committee Report Issue 8
  July 2024
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Michael Diz
  ,
  Gregory V. Gooding
  ,
  Elliot Greenfield
  ,
  Emily F. Huang
  ,
  Jonathan E. Levitsky
  ,
  Maeve O'Connor
  ,
  William D. Regner
  ,
  Jeffrey J. Rosen
  ,
  Katherine Durnan Taylor
  ,
  Caitlin Gibson
  ,
  Erik J. Andrén
  ,
  Matthew Ryan
• Federal Trade Commission Finalizes Updates to the Health Breach Notification Rule
  20 May 2024
  Andrew L. Bab
  ,
  Avi Gesser
  ,
  Paul D. Rubin
  ,
  Kim T. Le
  ,
  Melissa Runsten
  ,
  Johanna N. Skrzypczyk
  ,
  Hannah R. Levine
  ,
  Kaitlyn McGill
  ,
  Annabella M. Waszkiewicz
• Delaware Supreme Court Holds MFW Inapplicable Based on Banker Conflict Disclosure Deficiencies
  3 May 2024
  Andrew L. Bab
  ,
  Gregory V. Gooding
  ,
  Matthew E. Kaplan
  ,
  Jonathan E. Levitsky
  ,
  Maeve O'Connor
  ,
  William D. Regner
• MarketCheck – Spring 2024
  April 2024
  Andrew L. Bab
  ,
  Emily F. Huang
  ,
  Andrew G. Jamieson
  ,
  Jonathan E. Levitsky
  ,
  Katherine Durnan Taylor
  ,
  Caitlin Gibson
• California Lawmakers Target Private Equity and Hedge Fund Investment in Healthcare Facilities
  23 February 2024
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Kevin Rinker
  ,
  Kim T. Le
  ,
  Hannah R. Levine
• Private Equity Report: 2024 Outlook
  February 2024
  Christopher Anthony
  ,
  Katherine Ashton
  ,
  Andrew L. Bab
  ,
  Paul S. Bird
  ,
  Dominic Blaxill
  ,
  Ezra Borut
  ,
  Geoffrey P. Burgess
  ,
  Andrew J. Ceresney
  ,
  Charu A. Chandrasekhar
  ,
  Jennifer L. Chu
  ,
  Luke Dembosky
  ,
  E. Drew Dutton
  ,
  Jane Engelhardt
  ,
  Avi Gesser
  ,
  Andrew J. Gershon
  ,
  Nia I. Goodman
  ,
  David Grosgold
  ,
  Jyotin Hamid
  ,
  Ted Hassi
  ,
  Morgan J. Hayes
  ,
  Peter J. Irwin
  ,
  Eric T. Juergens
  ,
  Robert B. Kaplan
  ,
  M. Natasha Labovitz
  ,
  Jonathan F. Lewis
  ,
  Sidney P. Levinson
  ,
  Andrew M. Levine
  ,
  Erez Liebermann
  ,
  Timothy McIver
  ,
  Maura Kathleen Monaghan
  ,
  Edwin Northover
  ,
  Brett M. Novick
  ,
  Marc Ponchione
  ,
  Ryan T. Rafferty
  ,
  Natalie L. Reid
  ,
  Julie M. Riewe
  ,
  Kevin Rinker
  ,
  Samantha J. Rowe
  ,
  Paul D. Rubin
  ,
  Michael Schaper
  ,
  Kevin M. Schmidt
  ,
  Scott B. Selinger
  ,
  Aly Love (f/k/a Simons)
  ,
  Thomas Smith
  ,
  Kristin A. Snyder
  ,
  Steven J. Slutzky
  ,
  Ramya S. Tiller
  ,
  Patricia Volhard
  ,
  Erica S. Weisgerber
  ,
  Kyra K. Bromley
  ,
  Alison E. Buckley-Serfass
  ,
  Jennifer R. Cestaro
  ,
  Stuart Hammer
  ,
  Jin-Hyuk Jang
  ,
  Wen-Wei Lai
  ,
  Michael P. McGuigan
  ,
  Sheena Paul
  ,
  Melissa Runsten
  ,
  Tricia Bozyk Sherno
  ,
  Ulysses Smith
  ,
  Sergio Torres
  ,
  Elie J. Worenklein
  ,
  Adam Aukland-Peck
  ,
  Josephine Chen
  ,
  Perpétua B. Chéry
  ,
  Paul Eastham
  ,
  Isabelle Glimcher
  ,
  Yiran Ji
  ,
  Maryam Kanna
  ,
  Leah Martin
  ,
  Sophie Michalski
  ,
  Diana Moise
  ,
  David J. Swiedler
  ,
  Perri M. Weinstein
  ,
  Nathan R. Hogan
• Chevron Under Fire: What Healthcare and Life Sciences Investors Should Know
  19 January 2024
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
  ,
  Zoe Jacoby
  ,
  Adriana Kranjac
  ,
  Kaitlyn McGill
• Debevoise & Plimpton Special Committee Report Issue 7
  16 January 2024
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Michael Diz
  ,
  Gregory V. Gooding
  ,
  Elliot Greenfield
  ,
  Emily F. Huang
  ,
  Jonathan E. Levitsky
  ,
  Maeve O'Connor
  ,
  William D. Regner
  ,
  Jeffrey J. Rosen
  ,
  Katherine Durnan Taylor
  ,
  Caitlin Gibson
  ,
  Erik J. Andrén
  ,
  Jacob Dougherty
  ,
  Matthew Ryan
• California’s Office of Health Care Affordability Finalizes Health Care Transaction Notice Regulations
  12 January 2024
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Michael Diz
  ,
  Spencer K. Gilbert
  ,
  Kevin Rinker
  ,
  Matthew M. Delja
  ,
  Kim T. Le
  ,
  Hannah R. Levine
• Top 10 Healthcare and Life Sciences Issues to Watch in 2024
  4 January 2024
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Ted Hassi
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Michael Schaper
  ,
  Erica S. Weisgerber
  ,
  Kim T. Le
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
  ,
  Ilya Balabanovsky
  ,
  Margaret Howard
  ,
  Chaim Lapp
  ,
  Hannah R. Levine
  ,
  Zoe Jacoby
  ,
  Kaitlyn McGill
• CMS Announces First Ten Medicare Part D Drugs Subject to Price Negotiations
  6 October 2023
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
• California Regulators Publish Draft Regulations on Health Care Pre-Transaction Notice Requirements
  29 August 2023
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Kevin Rinker
  ,
  Kim T. Le
  ,
  Hannah R. Levine
• California Seeks to Increase Healthcare Workers’ Minimum Wage to $25/hour
  21 August 2023
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Meir D. Katz
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kim T. Le
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
• Artificial Intelligence in Healthcare: Balancing Risks and Rewards
  31 July 2023
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Avi Gesser
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Caroline P. Geiger
  ,
  Kim T. Le
  ,
  Tigist Kassahun
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
  ,
  Mengyi Xu
• Debevoise & Plimpton Special Committee Report Issue 6
  July 2023
  Andrew L. Bab
  ,
  Michael Diz
  ,
  Gregory V. Gooding
  ,
  Elliot Greenfield
  ,
  Emily F. Huang
  ,
  Jonathan E. Levitsky
  ,
  Maeve O'Connor
  ,
  William D. Regner
  ,
  Jeffrey J. Rosen
  ,
  Shannon Rose Selden
  ,
  Jonathan R. Tuttle
  ,
  Caitlin Gibson
  ,
  Erik J. Andrén
  ,
  Matthew Ryan
• FDA Guidance Offers Additional Clarity for Decentralized Clinical Trials
  30 May 2023
  Andrew L. Bab
  ,
  Paul D. Rubin
  ,
  Kim T. Le
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
• Artificial Intelligence and the Life Sciences Industry: FDA and FTC Regulatory Update
  16 May 2023
  Andrew L. Bab
  ,
  Avi Gesser
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
• Legal Dispute Surrounding Abortion Pill Has Significant Implications for Broader Healthcare Industry
  9 May 2023
  Andrew L. Bab
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Shannon Rose Selden
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
  ,
  Melissa Runsten
• New York Seeks Review and Approval Authority over Certain Healthcare Transactions
  7 March 2023
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Kim T. Le
  ,
  Hannah R. Levine
• Proceed with Caution: Online Tracking Technologies Pose HIPAA Compliance Risks
  2 March 2023
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Kim T. Le
  ,
  Hannah R. Levine
• Debevoise & Plimpton Special Committee Report Issue 5
  January 2023
  Andrew L. Bab
  ,
  Michael Diz
  ,
  Gregory V. Gooding
  ,
  Elliot Greenfield
  ,
  Emily F. Huang
  ,
  Jonathan E. Levitsky
  ,
  Maeve O'Connor
  ,
  William D. Regner
  ,
  Jeffrey J. Rosen
  ,
  Shannon Rose Selden
  ,
  Jonathan R. Tuttle
  ,
  Caitlin Gibson
  ,
  Erik J. Andrén
  ,
  Matthew Ryan
• Top 15 Healthcare and Life Sciences Issues to Watch in 2023
  9 January 2023
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Michael Schaper
  ,
  Erica S. Weisgerber
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Elie J. Worenklein
  ,
  Samuel J. Allaman
  ,
  Adam Aukland-Peck
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
  ,
  Adam C. Saunders
  ,
  Adrian St. Francis
  ,
  Emily G. Dennan
  ,
  Micah A. Rubin
• FTX Collapse Causes SEC to Request Additional Crypto Asset Disclosures
  13 December 2022
  Andrew L. Bab
  ,
  Morgan J. Hayes
  ,
  Sidney P. Levinson
  ,
  Benjamin R. Pedersen
  ,
  Katherine Durnan Taylor
  ,
  Elie J. Worenklein
  ,
  Chris Gallucci
  ,
  Ezra Newman
  ,
  Jonathan Steinberg
• Implications of the Inflation Reduction Act for Investors in Life Sciences Companies
  November 2022
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
• Private Equity Report Fall 2022, Vol 22, No 3
  November 2022
  Andrew L. Bab
  ,
  Sally Bergmann Hardesty
  ,
  Michael Bolotin
  ,
  Jennifer L. Chu
  ,
  Erin Cleary
  ,
  Matthew Dickman
  ,
  Gregory V. Gooding
  ,
  Mark P. Goodman
  ,
  Gareth Hughes
  ,
  Mark Johnson
  ,
  Meir D. Katz
  ,
  Henry Lebowitz
  ,
  Maurizio Levi-Minzi
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kevin M. Schmidt
  ,
  Scott B. Selinger
  ,
  Ramya S. Tiller
  ,
  Zhiyan Cao
  ,
  Caroline P. Geiger
  ,
  Kim T. Le
  ,
  Jin-Hyuk Jang
  ,
  Tigist Kassahun
  ,
  Hannah R. Levine
  ,
  Keith J. Slattery
  ,
  Sergio Torres
  ,
  Dominique Trudelle
  ,
  Hadel Alfagir
  ,
  David N. Simpser
• Structuring Options for Addressing the New 1% Excise Tax
  November 2022
  Andrew L. Bab
  ,
  Michael Bolotin
  ,
  Erin Cleary
  ,
  David N. Simpser
• Cautionary Tale from Delaware: Restrictive Covenants Binding Sellers Must Be Narrowly Tailored
  27 October 2022
  Andrew L. Bab
  ,
  Gregory V. Gooding
  ,
  Emily F. Huang
  ,
  Maeve O'Connor
  ,
  William D. Regner
  ,
  Jeffrey J. Rosen
  ,
  Caitlin Gibson
• Dealmaking Implications of California’s New Healthcare Cost Monitoring Law
  19 August 2022
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
• Debevoise & Plimpton Special Committee Report Issue 4
  August 2022
  Andrew L. Bab
  ,
  Michael Diz
  ,
  Gregory V. Gooding
  ,
  Elliot Greenfield
  ,
  Emily F. Huang
  ,
  Jonathan E. Levitsky
  ,
  Maeve O'Connor
  ,
  William D. Regner
  ,
  Jeffrey J. Rosen
  ,
  Shannon Rose Selden
  ,
  Jonathan R. Tuttle
  ,
  Erik J. Andrén
• Recent SCOTUS Decisions Impacting Healthcare
  3 August 2022
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
• FTC Sharpens Focus on Private Equity
  17 June 2022
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Ted Hassi
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Michael Schaper
  ,
  Erica S. Weisgerber
  ,
  Kim T. Le
  ,
  Leah Martin
  ,
  Adam C. Saunders
• California Poised to Grant Attorney General Broad Approval Authority over Healthcare Transactions
  16 June 2022
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
• Navigating the Dynamic World of Antitrust Divestitures
  May 2022
  Andrew L. Bab
  ,
  Ted Hassi
• Private Equity Report Spring 2022, Vol 22, No 1
  May 2022
  Catherine Amirfar
  ,
  Andrew L. Bab
  ,
  Megan K. Bannigan
  ,
  David H. Bernstein
  ,
  Alexander R. Cochran
  ,
  Avi Gesser
  ,
  Ted Hassi
  ,
  Eric T. Juergens
  ,
  Matthew E. Kaplan
  ,
  M. Natasha Labovitz
  ,
  Sidney P. Levinson
  ,
  Pierre Maugüé
  ,
  Marc Ponchione
  ,
  Ina C. Popova
  ,
  Natalie L. Reid
  ,
  Julie M. Riewe
  ,
  Scott B. Selinger
  ,
  Kristin A. Snyder
  ,
  Ramya S. Tiller
  ,
  Richard Ward
  ,
  Erica S. Weisgerber
  ,
  Charu A. Chandrasekhar
  ,
  Nick S. Kaluk III
  ,
  Sheena Paul
  ,
  Christopher Rosekrans
  ,
  Jennifer Wheater
  ,
  Paul Eastham
  ,
  Christopher S. Ford
  ,
  Christine Shu Gilleland
  ,
  Michael C. Godbe
  ,
  Kate Saba
• CLS Blue Sky Blog: Debevoise & Plimpton Discusses SEC’s Proposed SPAC Rules and Investment Banks
  2 May 2022
  CLS Blue Sky Blog
  Christopher Anthony
  ,
  Andrew L. Bab
  ,
  Morgan J. Hayes
  ,
  William D. Regner
  ,
  Gregory V. Gooding
• The Proposed SPAC Rules and Their Impact on Investment Banks
  27 April 2022
  Christopher Anthony
  ,
  Andrew L. Bab
  ,
  Gregory V. Gooding
  ,
  Morgan J. Hayes
  ,
  Peter J. Loughran
  ,
  William D. Regner
  ,
  Steven J. Slutzky
• Harvard Forum on Corporate Governance: Special Committee Report
  19 March 2022
  Harvard Forum on Corporate Governance
  Andrew L. Bab
  ,
  Gregory V. Gooding
  ,
  Jeffrey J. Rosen
  ,
  Maeve O'Connor
  ,
  Michael Diz
• Texas Federal Judge Sides with Providers in “No Surprises Act” Ruling
  1 March 2022
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
  ,
  Adriana Kranjac
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
• Debevoise & Plimpton Special Committee Report Issue 3
  February 2022
  Andrew L. Bab
  ,
  Michael Diz
  ,
  Gregory V. Gooding
  ,
  Elliot Greenfield
  ,
  Emily F. Huang
  ,
  Jonathan E. Levitsky
  ,
  Maeve O'Connor
  ,
  William D. Regner
  ,
  Jeffrey J. Rosen
  ,
  Shannon Rose Selden
  ,
  Jonathan R. Tuttle
• 2021/2022 Private Equity Year-End Review and Outlook
  January 2022
  Jonathan Adler
  ,
  Catherine Amirfar
  ,
  Christopher Anthony
  ,
  Katherine Ashton
  ,
  Andrew L. Bab
  ,
  Geoffrey P. Burgess
  ,
  Ezra Borut
  ,
  Andrew J. Ceresney
  ,
  Jennifer L. Chu
  ,
  Jeffrey P. Cunard
  ,
  Alexander R. Cochran
  ,
  E. Drew Dutton
  ,
  Jane Engelhardt
  ,
  Morgan J. Hayes
  ,
  Eric T. Juergens
  ,
  Maurizio Levi-Minzi
  ,
  Nicholas P. Pellicani
  ,
  Ryan T. Rafferty
  ,
  Julie M. Riewe
  ,
  Scott B. Selinger
  ,
  Marc Ponchione
  ,
  Thomas Smith
  ,
  Ramya S. Tiller
  ,
  Patricia Volhard
  ,
  Richard Ward
  ,
  Marshal L. Bozzo
  ,
  Christopher Dortschy
  ,
  Andrew J. Gershon
  ,
  Emily F. Huang
  ,
  Jennifer Wheater
  ,
  Dominic Blaxill
  ,
  Charles Cartiglia
  ,
  Robert T. Dura
  ,
  Matthew J. Sacco
  ,
  Sheng Shao
  ,
  Sergio Torres
  ,
  Charlotte A. Walkovik
  ,
  Paul Eastham
  ,
  Christopher Gossage
  ,
  Robert B. Kaplan
  ,
  Sheena Paul
  ,
  John Young
  ,
  Jin-Hyuk Jang
  ,
  Lukas Ott
  ,
  Andrew M. Levine
  ,
  Stuart Hammer
  ,
  Ulysses Smith
  ,
  Luke Dembosky
  ,
  Avi Gesser
  ,
  Peter J. Irwin
  ,
  Ina C. Popova
  ,
  Samantha J. Rowe
  ,
  M. Natasha Labovitz
  ,
  Sidney P. Levinson
  ,
  Paul D. Rubin
  ,
  Eric Dinallo
  ,
  Marilyn A. Lion
  ,
  Jacob W. Stahl
  ,
  Nicholas F. Potter
  ,
  Kim T. Le
  ,
  Adam Aukland-Peck
  ,
  Melissa Runsten
  ,
  Matthew Mrozek
  ,
  Michael C. Godbe
  ,
  Christel Y. Tham
  ,
  Lisa Wang Lachowicz
  ,
  Yiran Ji
• Debevoise & Plimpton Special Committee Report Issue 2
  September 2021
  Andrew L. Bab
  ,
  Michael Diz
  ,
  Gregory V. Gooding
  ,
  Elliot Greenfield
  ,
  Emily F. Huang
  ,
  Jonathan E. Levitsky
  ,
  Maeve O'Connor
  ,
  William D. Regner
  ,
  Jeffrey J. Rosen
  ,
  Shannon Rose Selden
  ,
  Jonathan R. Tuttle
• 2021 Private Equity Midyear Review and Outlook
  22 July 2021
  Jonathan Adler
  ,
  Christopher Anthony
  ,
  Katherine Ashton
  ,
  Andrew L. Bab
  ,
  Megan K. Bannigan
  ,
  Sally Bergmann Hardesty
  ,
  David H. Bernstein
  ,
  Paul S. Bird
  ,
  Ezra Borut
  ,
  Geoffrey P. Burgess
  ,
  Jennifer L. Chu
  ,
  Matthew Dickman
  ,
  Christopher Dortschy
  ,
  E. Drew Dutton
  ,
  Jane Engelhardt
  ,
  Peter A. Furci
  ,
  Avi Gesser
  ,
  Jyotin Hamid
  ,
  Morgan J. Hayes
  ,
  Peter J. Irwin
  ,
  Meir D. Katz
  ,
  Rafael Kariyev
  ,
  M. Natasha Labovitz
  ,
  Maurizio Levi-Minzi
  ,
  Andrew M. Levine
  ,
  Sidney P. Levinson
  ,
  Jonathan F. Lewis
  ,
  Marc Ponchione
  ,
  Ryan T. Rafferty
  ,
  Paul D. Rubin
  ,
  Zachary H. Saltzman
  ,
  Kevin M. Schmidt
  ,
  Shannon Rose Selden
  ,
  Scott B. Selinger
  ,
  Steven J. Slutzky
  ,
  Ramya S. Tiller
  ,
  Richard Ward
  ,
  Patricia Volhard
  ,
  Franci J. Blassberg
  ,
  Jeffrey P. Cunard
  ,
  Andrew J. Gershon
  ,
  Stuart Hammer
  ,
  Jin-Hyuk Jang
  ,
  Kim T. Le
  ,
  Sheena Paul
  ,
  Tricia Bozyk Sherno
  ,
  Jacob W. Stahl
  ,
  Jennifer Wheater
  ,
  John Young
  ,
  Adam Aukland-Peck
  ,
  Dominic Blaxill
  ,
  Charles Cartiglia
  ,
  Robert T. Dura
  ,
  Paul Eastham
  ,
  Jay E. Evans
  ,
  David J. Hotelling
  ,
  Samuel D. Krawiecz
  ,
  Wen-Wei Lai
  ,
  Robert Maddox
  ,
  Sergio Torres
  ,
  Malina Welman
• The American Rescue Plan Act of 2021: Implications for Healthcare and Life Sciences Companies
  12 March 2021
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
  ,
  Benjamin Leb
• Proposed Elimination of Medicaid Rebate Cap Could Negatively Impact Innovator Pharmaceutical Industry
  11 February 2021
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• Biden Takes Aim at Trump Administration Healthcare Policies
  2 February 2021
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• 2020/2021 Private Equity Year End Review and Outlook
  7 January 2021
  Jonathan Adler
  ,
  William D. Regner
  ,
  John W. Rife III
  ,
  Jennifer R. Cestaro
  ,
  Katherine Ashton
  ,
  E. Drew Dutton
  ,
  Jane Engelhardt
  ,
  Thomas Smith
  ,
  Ramya S. Tiller
  ,
  Christopher Anthony
  ,
  Kevin M. Schmidt
  ,
  Maurizio Levi-Minzi
  ,
  Geoffrey P. Burgess
  ,
  Dominic Blaxill
  ,
  Wen-Wei Lai
  ,
  Jyotin Hamid
  ,
  Morgan J. Hayes
  ,
  Steven J. Slutzky
  ,
  Richard Ward
  ,
  Jennifer Wheater
  ,
  Paul Eastham
  ,
  Peter A. Furci
  ,
  Rafael Kariyev
  ,
  Jay E. Evans
  ,
  Samuel D. Krawiecz
  ,
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Jyotin Hamid
  ,
  Meir D. Katz
  ,
  Jonathan F. Lewis
  ,
  Tricia Bozyk Sherno
  ,
  Ezra Borut
  ,
  Jeffrey P. Cunard
  ,
  Marc Ponchione
  ,
  Kenneth J. Berman
  ,
  Patricia Volhard
  ,
  Christopher Dortschy
  ,
  Jin-Hyuk Jang
  ,
  John Young
  ,
  Andrew J. Ceresney
  ,
  Robert B. Kaplan
  ,
  Julie M. Riewe
  ,
  Sally Bergmann Hardesty
  ,
  Scott B. Selinger
  ,
  Stuart Hammer
  ,
  Luke Dembosky
  ,
  Avi Gesser
  ,
  Jim Pastore
  ,
  Megan K. Bannigan
  ,
  David H. Bernstein
  ,
  M. Natasha Labovitz
  ,
  Sidney P. Levinson
  ,
  Peter J. Irwin
  ,
  Malina Welman
  ,
  Paul S. Bird
• Consolidated Appropriations Act: Implications for Healthcare and Life Sciences Companies
  30 December 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• The Trump Administration’s Final Drug Pricing Hurrah—Will It Last?
  24 November 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• COVID-19 Vaccines: FDA Regulatory Timeline and Next Steps Prior to Widespread Distribution
  20 November 2020
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Kevin Rinker
  ,
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jennifer L. Chu
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• The Potential Impact of a Biden Administration on Life Sciences, Healthcare, and Consumer Product Companies and Investors
  2 November 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• Third Circuit Strikes Another Blow Against the FTC’s Preferred Enforcement Power, Setting the Stage for a Supreme Court Showdown
  5 October 2020
  Andrew L. Bab
  ,
  David H. Bernstein
  ,
  Ted Hassi
  ,
  Paul D. Rubin
  ,
  Leah Martin
  ,
  Melissa Runsten
• Trump’s Newest Drug Pricing Executive Order: Still Much More Bark than Bite
  16 September 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• HHS Announces Additional CARES Act Funding for Qualifying Providers
  4 August 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• Trump’s New Drug Pricing Executive Orders: Much More Bark Than Bite
  29 July 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• HHS Issues Additional Guidance on Qualifications for CARES Act Funding
  8 May 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Appropriations for Healthcare Providers Related to COVID-19
  30 April 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• New Appropriation for Healthcare Providers
  24 April 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• HHS Announces Additional Funding for Healthcare Providers Impacted by COVID-19
  23 April 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Sponsor Backed PIPEs: COVID-19 and the Race for Liquidity
  22 April 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Gary M. Friedman
  ,
  Gregory V. Gooding
  ,
  Uri Herzberg
  ,
  Jonathan E. Levitsky
  ,
  Sunil William Savkar
  ,
  Kevin M. Schmidt
  ,
  Shannon Rose Selden
  ,
  Katherine Durnan Taylor
  ,
  Steven J. Slutzky
• HHS Distributing $30 Billion in Grants to Medicare Providers
  10 April 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• CMS Announces Intent to Provide $30 Billion to Medicare Providers
  9 April 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Rethinking Poison Pills, Again
  9 April 2020
  Andrew L. Bab
  ,
  Gregory V. Gooding
  ,
  William D. Regner
  ,
  Sergio Torres
• Update Regarding Public Health and Social Services Emergency Fund
  6 April 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• The Federal Government Throws a Lifeline to Medicare Providers and Suppliers
  30 March 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• CARES Act: Implications for Healthcare and Life Science Companies and Investors
  27 March 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Indian Pharma: Congress and FDA Continue Scrutiny of Foreign Drug Companies with Heightened Focus on Companies Located in India
  12 February 2020
  Andrew L. Bab
  ,
  Geoffrey P. Burgess
  ,
  Jennifer L. Chu
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Suchita Mandavilli Brundage
  ,
  Melissa Runsten
• What the Bipartisan Budget Agreement Means for the Healthcare Industry and Life Sciences Companies
  23 December 2019
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Ted Hassi
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Leah Martin
• The Private Equity Report Fall 2019, Vol 19, No 2
  November 2019
  Andrew L. Bab
  ,
  Uri Herzberg
  ,
  Eric T. Juergens
  ,
  Matthew E. Kaplan
  ,
  Henry Lebowitz
  ,
  Paul M. Rodel
  ,
  Jeffrey E. Ross
  ,
  Scott B. Selinger
  ,
  Patricia Volhard
  ,
  Joshua M. Samit
  ,
  John Young
  ,
  Spencer K. Gilbert
  ,
  Ryan T. Rafferty
• Royalty Financing: An Appealing Alternative to Traditional Life Sciences Financing
  November 2019
  Andrew L. Bab
  ,
  Henry Lebowitz
• Congressional Investigation Highlights Potential Risks for Private Equity Healthcare Investments
  19 September 2019
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Maura Kathleen Monaghan
  ,
  David A. O'Neil
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kevin M. Schmidt
  ,
  Jacob W. Stahl
• Court Strikes Down Regulation Requiring Price Disclosure in TV Ads for Prescription Drugs
  11 July 2019
  Andrew L. Bab
  ,
  David H. Bernstein
  ,
  Jyotin Hamid
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• SEC Proposes to Eliminate Auditor Attestation Requirement for Low-Revenue Reporting Companies
  23 May 2019
  Andrew L. Bab
  ,
  Morgan J. Hayes
  ,
  Matthew E. Kaplan
  ,
  Peter J. Loughran
  ,
  Paul M. Rodel
  ,
  Steven J. Slutzky
  ,
  Eric T. Juergens
• Private Equity Guide to Consumer Product Investing Under the Trump Administration: Food and Drug Administration (FDA) Developments
  18 April 2019
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Michael Diz
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kevin M. Schmidt
  ,
  Melissa Runsten
• Affordable Care Act Likely to Survive Latest Challenge
  19 December 2018
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• A Post-Election Survey Of The Health Care Ecosystem
  9 November 2018
  Law360
  Andrew L. Bab
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• The 2018 Elections: Winners and Losers in the Healthcare Ecosystem
  9 November 2018
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• CMS’ Proposed Part B Price Controls: Hurdles and Unintended Consequences
  5 November 2018
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• CMS’ Proposed Rule Regarding Disclosure of Drug “List Prices” in Television Ads: Needed Transparency or Recipe for Confusion?
  23 October 2018
  Andrew L. Bab
  ,
  David H. Bernstein
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Jared I. Kagan
  ,
  Melissa Runsten
• Yes, Virginia, there is an MAE
  2 October 2018
  Gregory V. Gooding
  ,
  William D. Regner
  ,
  Andrew L. Bab
• Fourth Circuit Decision Casts Doubt on State Efforts to Regulate Drug Pricing
  18 May 2018
  Bloomberg Law
  Andrew L. Bab
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• The White House’s Drug Pricing “Blueprint”
  18 May 2018
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• Private Equity Guide to Life Sciences Investing Under the Trump Administration: Food and Drug Administration (FDA) Developments
  15 March 2018
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
• Perpetually Liable? What the California Supreme Court Decision Means for Innovator Pharmaceutical Companies
  22 February 2018
  Toxics Law Reporter
  Andrew L. Bab
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• The Latest on the Trump Administration’s Drug Pricing Initiatives
  21 February 2018
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• T.H. v. Novartis: Implications for Companies That Have Sold or Are Considering Selling the Rights to Innovator Drugs
  19 January 2018
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
• A Look At Recent Efforts To Contain Health Care Costs
  5 January 2018
  Law360
  Andrew L. Bab
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• How Tax Reform and Other Recent Developments Could Impact the Healthcare Industry
  20 December 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Peter A. Furci
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• New Public and Private Efforts to Contain Healthcare Costs: What it Means for the Healthcare Industry
  20 December 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• Law360: How Tax Reform Could Impact the Health Care Industry
  15 November 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Peter A. Furci
  ,
  Mark P. Goodman
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• The “Tax Cuts and Jobs Act” – How It Impacts the Healthcare Industry
  7 November 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Gary M. Friedman
  ,
  Peter A. Furci
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Where Does Healthcare Reform Stand?
  31 October 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• How Section 1332 Waivers Could Impact Health Care Reform
  24 July 2017
  Law 360
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Health Care Winners And Losers From The Better Care Act
  29 June 2017
  Law 360
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• The “Better Care Act”: Winners and Losers in the Healthcare Industry
  28 June 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• The Senate’s Healthcare Bill – What’s In It?
  28 June 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Finally A Health Care Reform Plan Passes the House – What’s in the Bill and What it Means for the Healthcare Industry
  5 May 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Shining A Light On GOP Plan For Health Care Reform
  7 March 2017
  Law360
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Just a Bit of Clarity – Recent Developments Shine Some Light on Trump and GOP Plans for Healthcare Reform
  27 February 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Kevin Rinker
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• The Outlook For The Pharmaceutical Industry Under Trump
  12 January 2017
  Law360
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• The Outlook On Drug Pricing: At What Cost?
  14 December 2016
  Law360
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Still in the Waiting Room: Outlook for the Healthcare Industry Under the Trump Administration
  15 November 2016
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Gary M. Friedman
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Another Rural/Metro Lesson for Sell-Side Advisors: Bank Agrees to Pay $2.5 Million to SEC to Settle Proxy Statement Claims
  2 September 2016
  Andrew L. Bab
  ,
  Gregory V. Gooding
  ,
  William D. Regner
• New York Adopts Delaware's MFW Standard for Going-Private Mergers
  6 May 2016
  Andrew L. Bab
  ,
  Gregory V. Gooding
  ,
  Gary W. Kubek
  ,
  Maeve O'Connor
  ,
  William D. Regner
• Key Issues In U.S. Going Private Transactions
  1 April 2016
  The M&A Lawyer
  Andrew L. Bab
  ,
  Paul S. Bird
• Delaware Supreme Court Affirms “Narrow” Rural/Metro Ruling; Declines to Characterize Sell-Side Financial Advisors as “Gatekeepers”
  1 December 2015
  Andrew L. Bab
  ,
  Gregory V. Gooding
  ,
  Gary W. Kubek
  ,
  Maeve O'Connor
  ,
  William D. Regner
• In re Dole Food Co.: When Stockholders Deserve a Fairer Price
  28 August 2015
  Andrew L. Bab
  ,
  Gregory V. Gooding
  ,
  Gary W. Kubek
  ,
  Maeve O'Connor
  ,
  William D. Regner
• Ninth Circuit Affirms District Court Order to Unwind Hospital Merger
  13 February 2015
  Gary W. Kubek
  ,
  Mark P. Goodman
  ,
  Andrew L. Bab
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Kristin D. Kiehn
  ,
  Erica S. Weisgerber
• The Inversion Craze: What You Need to Know
  Fall 2014
  Gary M. Friedman
  ,
  Andrew L. Bab
  ,
  Kevin Rinker
• Lot of Inversion Talk, but Do You Know the Basics?
  7 August 2014
  Law360
  Andrew L. Bab
  ,
  Gary M. Friedman
  ,
  Kevin Rinker
• Tender Offers Poised to Become an Acquisition Structure
  Spring 2013
  Andrew L. Bab
• The Private Equity Report
  Spring 2013
  Gregory V. Gooding
  ,
  William D. Regner
  ,
  Gary W. Kubek
  ,
  David A. Brittenham
  ,
  Satish M. Kini
  ,
  Christopher Rosekrans
  ,
  David Innes
  ,
  Geoffrey P. Burgess
  ,
  Guy Lewin-Smith
  ,
  Andrew L. Bab
  ,
  M. Natasha Labovitz
  ,
  Sally Gibson
  ,
  Michael P. Harrell
• Recent Developments in the Russian Pharmaceutical Industry
  31 May 2013
  Andrew L. Bab
  ,
  Kevin Rinker
• Delaware Court Applies Business Judgment Review to Going Private Merger
  30 May 2013
  Andrew L. Bab
  ,
  Gregory V. Gooding
  ,
  Gary W. Kubek
  ,
  William D. Regner
• Got Financing? You May Have to Extend Your Tender Offer
  23 April 2013
  The Harvard Law School Forum on Corporate Governance and Financial Regulation
  Andrew L. Bab
  ,
  David A. Brittenham
  ,
  Matthew E. Kaplan
  ,
  Alan H. Paley
• Got Financing? You May Have to Extend Your Tender Offer
  5 April 2013
  Andrew L. Bab
  ,
  David A. Brittenham
  ,
  Matthew E. Kaplan
  ,
  Alan H. Paley
• Delaware Proposes to Eliminate Need for Stockholder Vote in Most Two-Step Deals
  22 March 2013
  Andrew L. Bab
  ,
  Gregory V. Gooding
  ,
  William D. Regner
• Supreme Court Upholds 2010 Patient Protection and Affordable Care Act
  29 June 2012
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
• Delaware Court Enjoins Martin Marietta’s Unsolicited Offer For Vulcan Based on NDA Breaches
  8 May 2012
  Andrew L. Bab
  ,
  Gregory V. Gooding
  ,
  Gary W. Kubek
  ,
  William D. Regner
• Contingent Value Rights for Private Equity-Backed Healthcare M&A
  24 October 2011
  Mergers & Acquisitions
  Andrew L. Bab
• The Current State of the Poison Pill
  July/August 2011
  Deal Lawyers
  Andrew L. Bab
• Supreme Court Rules in Two Pharma Cases
  29 June 2011
  Anne E. Cohen
  ,
  Andrew L. Bab
  ,
  Kevin Rinker
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
• The Private Equity Report
  Spring 2011
  Franci J. Blassberg
  ,
  Michael P. Harrell
  ,
  Satish M. Kini
  ,
  Lawrence K. Cagney
  ,
  Jonathan F. Lewis
  ,
  Matthew E. Kaplan
  ,
  Gregory V. Gooding
  ,
  Jonathan E. Levitsky
  ,
  Paul D. Brusiloff
  ,
  Elizabeth Pagel Serebransky
  ,
  Maurizio Levi-Minzi
  ,
  E. Drew Dutton
  ,
  Andrew L. Bab
  ,
  Jonathan Adler
  ,
  Anne-Lise Quach
• Head of Senate Subcommittee on Antitrust Sounds Alarm on Drug Shortages
  26 May 2011
  Daniel M. Abuhoff
  ,
  Andrew L. Bab
  ,
  Kevin Rinker
• Poison Pills 2011
  3 April 2011
  The Harvard Law School Forum on Corporate Governance and Financial Regulation
  Andrew L. Bab
• Contingent Value Rights in Healthcare M&A
  April 2011
  Insights
  Andrew L. Bab
  ,
  Gary M. Friedman
• Poison Pills in 2011
  March 2011
  Director Notes, a Conference Board publication
  Andrew L. Bab
• Delaware Court of Chancery Upholds Airgas Poison Pill, Ending Takeover Battle
  17 February 2011
  Andrew L. Bab
  ,
  Paul S. Bird
  ,
  Gary W. Kubek
  ,
  William D. Regner
  ,
  Jeffrey J. Rosen
• Delaware Court of Chancery Upholds Airgas Bylaw Shortening Period Between Annual Meetings
  11 October 2010
  William D. Regner
  ,
  Gary W. Kubek
  ,
  Paul S. Bird
  ,
  Andrew L. Bab
• Delaware Supreme Court Upholds Validity of NOL Rights Plan
  5 October 2010
  Paul S. Bird
  ,
  Andrew L. Bab
  ,
  William D. Regner
• Mission Impossible
  3 May 2010
  The Deal Magazine and Northrop Grumman Corporation Law Department Ex/Im Daily Update
  Andrew L. Bab
• The Private Equity Report
  Winter 2010
  Franci J. Blassberg
  ,
  Matthew E. Kaplan
  ,
  Geoffrey P. Burgess
  ,
  Stuart Hammer
  ,
  Richard Ward
  ,
  Gary M. Friedman
  ,
  Andrew L. Bab
• Poison Pill Update: Delaware Chancery Court Upholds NOL Rights Plan with 4.99% Trigger
  2 March 2010
  Paul S. Bird
  ,
  Andrew L. Bab
  ,
  William D. Regner
• The Private Equity Report
  Spring 2009
  Franci J. Blassberg
  ,
  Andrew L. Bab
  ,
  Kenneth J. Berman
  ,
  Gary M. Friedman
  ,
  Richard F. Hahn
  ,
  Peter J. Irwin
  ,
  Marcia L. MacHarg
  ,
  Nicole Levin Mesard
  ,
  Kevin Rinker
  ,
  Matthew D. Saronson
  ,
  Philipp von Holst
• Delaware Supreme Court Overturns Lyondell Decision on Revlon and the Duty of Good Faith
  26 March 2009
  Andrew L. Bab
  ,
  Gary W. Kubek
  ,
  Jeffrey J. Rosen
  ,
  William D. Regner
• Delaware Dismisses Claims Alleging Failure to Monitor Risk: In Re Citigroup Inc. Shareholder Derivative Litigation
  27 February 2009
  William D. Regner
  ,
  Gary W. Kubek
  ,
  Andrew L. Bab
  ,
  Jeffrey J. Rosen
  ,
  Colby A. Smith
• Pre- and Post-Signing Discussions Found Not to Violate Sherman Act
  2 February 2009
  Andrew L. Bab
• Delaware Supreme Court Holds Shareholder Ratification Inapplicable to Actions that Require Shareholder Votes
  29 January 2009
  William D. Regner
  ,
  Gary W. Kubek
  ,
  Andrew L. Bab
  ,
  Jeffrey J. Rosen
• The Private Equity Report
  Fall 2008
  Franci J. Blassberg
  ,
  Gregory V. Gooding
  ,
  Paul L. Lee
  ,
  Peter F.G. Schuur
  ,
  Michael Bolotin
  ,
  Peter A. Furci
  ,
  Jonathan F. Lewis
  ,
  E. Drew Dutton
  ,
  Andrew L. Bab
  ,
  Dr. Thomas Schürrle
  ,
  Paul R. Berger
  ,
  Paul S. Bird
  ,
  William D. Regner
  ,
  Richard F. Hahn
  ,
  Jasmine Ball
• The Private Equity Report
  Summer 2007
  Franci J. Blassberg
  ,
  Kevin M. Schmidt
  ,
  Robert F. Quaintance, Jr.
  ,
  Andrew L. Bab
  ,
  Gary W. Kubek
  ,
  Jasmine Ball
• The Private Equity Report
  Spring 2006
  Franci J. Blassberg
  ,
  Woodrow W. Campbell, Jr.
  ,
  James A. Kiernan III
  ,
  Molly F. Stockley
  ,
  Andrew L. Bab
  ,
  Gary W. Kubek
  ,
  Richard Ward
  ,
  Pierre-Pascal Bruneau
  ,
  David F. Hickok
  ,
  Rebecca F. Silberstein
• The Private Equity Report
  Winter 2005
  Franci J. Blassberg
  ,
  Rebecca F. Silberstein
  ,
  Geoffrey Kittredge
  ,
  Andrew L. Bab
  ,
  Kenneth J. Berman
  ,
  Lawrence K. Cagney
  ,
  Antoine F. Kirry
• The Private Equity Report
  Winter 2004
  Franci J. Blassberg
  ,
  David J. Schwartz
  ,
  Rebecca F. Silberstein
  ,
  Antoine F. Kirry
  ,
  Marcia L. MacHarg
  ,
  Adele M. Karig
  ,
  Andrew L. Bab
  ,
  Peter A. Furci
  ,
  Jeffrey J. Rosen
  ,
  Kenneth J. Berman
  ,
  Michael P. Harrell
• The Private Equity Report
  Summer 2003
  Michael P. Harrell
  ,
  Marwan Al-Turki
  ,
  Adele M. Karig
  ,
  Gary M. Friedman
  ,
  Andrew L. Bab
  ,
  David A. Brittenham
  ,
  Alan J. Davies
  ,
  Franci J. Blassberg
  ,
  Jeffrey P. Cunard
  ,
  Kenneth J. Berman
• The Private Equity Report
  Spring 2003
  Franci J. Blassberg
  ,
  Michael P. Harrell
  ,
  Adele M. Karig
  ,
  Jeffrey S. Wood
  ,
  Andrew L. Bab
  ,
  William D. Regner
  ,
  Marcia L. MacHarg
• The Private Equity Report
  Spring 2001
  Franci J. Blassberg
  ,
  William B. Beekman
  ,
  Elizabeth Pagel Serebransky
  ,
  Andrew L. Bab
  ,
  Gary M. Friedman
  ,
  Woodrow W. Campbell, Jr.